CONCLUSIONS
At present, the treatment for NARDS is mainly PS replacement therapy and ad adjunctive supportive therapy. Budesonide is a powerful local anti-inflammatory drug, and a large number of animal and clinical trials have demonstrated that the utilization of budesonide could reduce the incidence of BPD, duration of assisted ventilation, and hospitalization. Therefore, it is reasonable to suppose that budesonide may be an effective drug for the treatment of NARDS. This review summarizes the current state of research on the effects of budesonide in ARDS in terms of clinical aspects and related mechanisms; our findings may provide new insights for clinical application. However, questions remain regarding the possible mechanisms of budesonide in the treatment of NARDS. Further clinical and experimental data are still needed to demonstrate the safety and efficacy of budesonide in the treatment of NARDS.